NEW YORK (dpa-AFX Broker) - Analyst firm Jefferies has lowered its target price for Evotec from 28 to 16 euros, but left its rating at "Buy". The drug discovery company's outlook remains vague ahead of the start of the new CEO in July, analyst Benjamin Jackson wrote in his study published on Monday. However, he remains very optimistic for the second half of the year, the importance of which may be underestimated./ag/zb

Publication of the original study: 19.05.2024 / 16:00 / ET

First distribution of the original study: 19.05.2024 / 19:05 / ET

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------